Skip to main content

Domani inizia AHA23. Ecco la lista dei Late Breaking Trials

Redazione By 10 Novembre 2023No Comments
Dai congressiNews
AHA23 trials

Si terranno dall’11 al 13 novembre a Philadelphia le Scientific Sessions 2023 dell’American Heart Association (#AHA23). L’evento, uno tra i più importanti al mondo nell’ambito della ricerca cardiovascolare, si prospetta particolarmente interessante dal punto di vista delle novità scientifiche. “Una mia previsione: questo weekend inizia un nuovo capitolo della medicina”, ha scritto John Mandrola, elettrofisiologo e autore per Medscape e Sensible Medicine. Riportiamo di seguito l’elenco degli Late Breaking Trials che saranno presentati nel corso delle tre giornate congressuali:

LBS.01: Obesity — Novel Therapeutics and Implications for Population Health

  • SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

 LBS.02: Hot Topics in Management of Coronary Artery Disease/Acute Coronary Syndrome

  • MINT: Restrictive Versus Liberal Blood Transfusion in Patients With Myocardial Infarction and Anemia: Results of the MINT Trial
  • ORBITA-2: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial
  • DAPA-MI: DAPA-MI – A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes

LBS.03: Heart Failure — VADS, Kids and Money

  • ARIES HeartMate 3: Avoidance of Aspirin With Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Clinical Trial
  • TEAMMATE: The TEAMMATE Trial: Everolimus to Prevent Rejection in Children After Cardiac Transplantation 
  • Integrating Cost Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Trial Providing Out-of-Pocket Costs for Heart Failure Medications During Clinical Encounters

LBS.04: Using Drugs, Diet and Delivery to Optimize Hypertension Outcomes

  • CARDIA-SSBP: Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals: A Randomized Order Cross-Over Trial
  • POP-HT: Long-Term Blood Pressure Control After Physician Optimized Postpartum Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial
  • KARDIA-1: Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension
  • CRHCP: Effectiveness of Blood Pressure-Lowering Intervention on Risk of Total Dementia Among Patients With Hypertension: A Cluster-Randomized Effectiveness Trial

LBS.05: Shocking Decisions in AFib Care

  • Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients With Atrial Fibrillation
  • AZALEA-TIMI 71: Abelacimab, a Novel Factor XI/XIa Inhibitor, versus Rivaroxaban in Patients With Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial
  • NOAH-AFNET 6: Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours: The NOAH-AFNET 6 Trial
  • ARTESIA: Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation

 LBS.06: Future of Lipid Lowering Therapy  Novel Mechanisms and Approaches

  • REPRIEVE: Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV
  • REMAIN-2: Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia (REMAIN-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
  • Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a)
  • Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial

 LBS.07: From Local to Global: Achieving Equity in Prevention

  • HTN Program: Hypertension Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial
  • A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients
  • ESPRIT: Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events
  • IMPACTS: Effect of a Multifaceted Implementation Strategy on Blood Pressure Control in Low-Income Patients: A Cluster Randomized Trial

LBS.08: Artificial Intelligence at the Bedside

  • SPEC-AI: Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial
  • ORFAN: Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study
  • Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients
  • ARISE: Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction Using Electrocardiogram (ARISE): A Pragmatic Randomized Controlled Trial